Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMQ4GC)

• Drug Name: SIPATRIGINE Drug Info
• Synonyms: Sipatrigine; 130800-90-7; Sipatrigine [INN:BAN]; 619C89; 2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidin-4-amine; UNII-OON9AVW1T3; BW619C89; BW-619C89; BW 619C89; OON9AVW1T3; CHEMBL28854; CHEBI:34977; 2-(4-Methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-4-pyrimidinamine; 4-Amino-2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)pyrimidine; 4-Pyrimidinamine, 2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-; AC1Q3LMC; AC1L1TYB; MLS006010764; SCHEMBL135888; C16H17Cl3N4; DTXSID20156750; MolPort-023-277-047

Indication

Disease Entry	ICD 11	Status	REF
Neurological disorder	6B60	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 60803
  ChEBI ID: CHEBI:34977
  CAS Number: CAS 130800-90-7
  TTD Drug ID: DMMQ4GC
  VARIDT Drug ID: DR00807

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.4 (SCN4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lanperisone	DM4EGPN	Musculoskeletal disorder	FA00-FC0Z	Phase 3	[6]
V-102862	DMR2EUV	N. A.	N. A.	Discontinued in Phase 1	[7]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[8]
veratridine	DMUF8JZ	Discovery agent	N.A.	Investigative	[8]
BW-202W92	DMFKXMT	Discovery agent	N.A.	Investigative	[5]
CCNCSSKWCRDHSRCC	DMBGHTW	Discovery agent	N.A.	Investigative	[9]
CCNCSSKWCRAHSRCC	DM96YR2	Discovery agent	N.A.	Investigative	[9]
CCACSSKWCRDHSRCC	DMSE20Y	Discovery agent	N.A.	Investigative	[9]
CCNCASKWCRDHSRCC	DMRFA5O	Discovery agent	N.A.	Investigative	[9]
ZNCCNCSSKWCRDHSRCC	DMY2V37	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.7 (SCN9A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XEN-402	DMR69CG	Osteoarthritis	FA00-FA05	Phase 2	[10]
PF-05089771	DMD74BJ	Chronic pain	MG30	Phase 2	[11]
BIIB074	DMLV1ET	Bipolar disorder	6A60	Phase 2	[12]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[12]
BIIB095	DMUC6EP	Pain	MG30-MG3Z	Phase 1	[12]
GDC0310	DMUNFEP	Chronic pain	MG30	Phase 1	[13]
DSP-3905	DMYHU24	Neuropathic pain	8E43.0	Phase 1	[12]
PF-05241328	DM2NTBL	Pain	MG30-MG3Z	Phase 1	[14]
DWJ-208	DMQKDJZ	Cancer related pain	MG30	Phase 1	[12]
RG7893	DM1R4MQ	Pain	MG30-MG3Z	Phase 1	[15]

Drug(s) Targeting Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARC029	DMYNJHI	Alzheimer disease	8A20	Phase 3	[16]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[17]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[18]
CGS-27830	DM8TLY3	N. A.	N. A.	Terminated	[19]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[20]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[21]
(-)-(S)-BayK8644	DMEA9KH	Discovery agent	N.A.	Investigative	[21]
CV-4093	DM983QP	Discovery agent	N.A.	Investigative	[16]
[3H](+)-isradipine	DM7QE1J	Discovery agent	N.A.	Investigative	[22]
MEBUDIPINE	DM0P59E	Discovery agent	N.A.	Investigative	[23]

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[24]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[25]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[26]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[27]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[28]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[2]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[29]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[13]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[30]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[31]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.5 (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mephenytoin	DM5UGDK	Epilepsy	8A60-8A68	Approved	[24]
Mexiletine	DMCTE9R	Ventricular tachycardia	BC71	Approved	[32]
Fosphenytoin	DMOX3LB	Epilepsy	8A60-8A68	Approved	[24]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[32]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[2]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[33]
Dyclonine	DMU6OFP	Pain	MG30-MG3Z	Approved	[34]
Moricizine	DMOMBJW	Arrhythmia	BC9Z	Approved	[35]
Ethotoin	DMXWOCP	Complex partial seizure	8A68.0	Approved	[36]
Prilocaine	DMI7DZ2	Pain	MG30-MG3Z	Approved	[34]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.8 (SCN10A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[37]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[38]
Bupivacaine	DM4PRFC	Anaesthesia	9A78.6	Approved	[38]
Tiapride	DMN6CAG	Alcohol dependence	6C40.2	Approved	[39]
Tetracaine	DM9J6C2	Spinal anesthesia	MB40.3	Approved	[40]
Proparacaine	DMLS39E	Anaesthesia	9A78.6	Approved	[38]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[41]
VX-150	DMGDB21	Neuropathic pain	8E43.0	Phase 2	[13]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[12]
PF-01247324	DM93LMS	Pain	MG30-MG3Z	Phase 1	[42]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.3 (SCN3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[28]
Aryl carboxamide derivative 1	DMTZRCW	N. A.	N. A.	Patented	[43]
Aryl carboxamide derivative 2	DM146TA	N. A.	N. A.	Patented	[43]
Pyrimidine derivative 1	DMN9VQM	N. A.	N. A.	Patented	[43]
Pyrrolo-pyridinone derivative 6	DMXGNP8	N. A.	N. A.	Patented	[43]
Pyrrolo-pyridinone derivative 5	DMK2FSY	N. A.	N. A.	Patented	[43]
U-92032	DMTYO3P	N. A.	N. A.	Terminated	[44]
PD-85639	DMNUKB4	N. A.	N. A.	Terminated	[28]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[45]
veratridine	DMUF8JZ	Discovery agent	N.A.	Investigative	[45]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Inhibitor	[2]
Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)	TT7RGTM	CAC1D_HUMAN	Inhibitor	[3]
Voltage-gated sodium channel alpha Nav1.3 (SCN3A)	TTAXZ0K	SCN3A_HUMAN	Inhibitor	[4]
Voltage-gated sodium channel alpha Nav1.4 (SCN4A)	TT84DRB	SCN4A_HUMAN	Inhibitor	[5]
Voltage-gated sodium channel alpha Nav1.5 (SCN5A)	TTZOVE0	SCN5A_HUMAN	Inhibitor	[2]
Voltage-gated sodium channel alpha Nav1.7 (SCN9A)	TT4G2JS	SCN9A_HUMAN	Inhibitor	[5]
Voltage-gated sodium channel alpha Nav1.8 (SCN10A)	TT90XZ8	SCNAA_HUMAN	Inhibitor	[5]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003904)
• [2] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [3] Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995).
• [4] Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. J Med Chem. 2002 Aug 15;45(17):3755-64.
• [5] Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
• [6] Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
• [7] 3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52.
• [8] Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2653-8.
• [9] Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
• [10] Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5.
• [11] Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127.
• [12] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740)
• [16] Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
• [17] Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem. 1995 May 12;38(10):1579-81.
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
• [19] CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993).
• [20] Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 530).
• [22] alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001 Jun 22;276(25):22100-6.
• [23] Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg Med Chem. 2010 May 1;18(9):3147-58.
• [24] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [25] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [26] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [27] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [28] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [29] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [30] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [31] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [32] Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
• [33] Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
• [34] Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
• [35] From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
• [36] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [37] Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
• [38] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [39] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [40] Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
• [41] Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
• [42] Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.
• [43] Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
• [44] Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
• [45] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).